| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
MaxCyte, Inc.$1.05
0 (0%)
F 13Pipeline Score Tools & Services · Clinical
Market Cap
111.41 M
EPS
-0.37
P/E Ratio
-
Value Trade
1.07 M
SEC Financials
Q1 2026Dilution Risk
Revenue
9.65 M
R&D Expenses
3.86 M
Operating CF
-8.17 M
Total Assets
194.47 M
Total Liabilities
26.59 M
Equity
167.89 M
D/E Ratio
12,345
-4.59 %
Week
19.51 %
1 Month
40.37 %
3 Month
-36.2 %
6 Month
-93.88 %
5 Year
-93.88 %
All Time
Cash Data
Cash Position
106.85 M
Monthly Burn
2.72 M
Runway
36.7 mo
Burn Trend
StableSEC Filing
May 13, 2026
Overview
Volume
478.64 K
52 Week Range
0.64 - 2.40
% held by Insiders
7.77 %
% held by Institutions
67.13 %
Enterprise Value
22.04 M
Total Shares
107.16 M
Short %
1.46 %
Float Shares
96.66 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for MaxCyte, Inc.
150Total events
3Upcoming
45Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 2
TBD
T2Quarterly Update
Subscribe to view catalyst details
TBD
T2Quarterly Update
Subscribe to view catalyst details
Event history 2
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
TBD
▲Partnership / LicenseCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F13
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 10%
Micro Cap (rank 823 of 913)
Percentile RankMaxCyte, Inc. has significant pipeline risk (13/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MXCT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MXCT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MXCT▲ +5.1%on this news
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
MaxCyte has announced a technology license partnership with Genentech to enhance cell therapy development. The agreement grants Genentech access to MaxCyte's ExPERT GTx platform and other technologies, facilitating cell engineering applications. This collaboration aims to support multiple programs and streamline workflows from research to manufacturing, showcasing MaxCyte's expertise in cell therapies.
Read more →MXCTMaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026
MaxCyte, Inc. will release its financial results for Q2 2026 on August 12, 2026, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss these results. Investors are encouraged to register online in advance for the call, which will also be available via webcast.
Read more →MXCTVectorBuilder Partners With MaxCyte® to Advance Clinical-Grade Cell Engineering
VectorBuilder has announced a partnership with MaxCyte to enhance clinical-grade cell engineering. This collaboration aims to leverage both companies' strengths in cell engineering technologies. Further details on the specific objectives or expected outcomes of this partnership were not provided in the announcement.
Read more →MXCT▲ +24.1%on this news
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance
MaxCyte reported a total revenue of $9.7 million for Q1 2026, including $6.2 million in core revenue. The company reiterated its full year revenue guidance of $30-32 million and announced a $10 million share repurchase program. CEO Maher Masoud expressed confidence in their performance and growth strategy, highlighting advancements in their SPL portfolio.
Read more →MXCT▼ -6.8%on this news
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
MaxCyte, Inc. will announce its financial results for Q1 2026 on May 12, 2026, after market close. A conference call will follow at 4:30 p.m. ET to discuss these results. Investors are encouraged to register online for the call, which will also be available via webcast. MaxCyte focuses on cell-engineering technologies to support therapeutic development.
Read more →MXCT▲ +5.9%on this news
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 31, 2026
MaxCyte, Inc. has announced the granting of inducement awards to Parmeet Ahuja, its new Chief Financial Officer. The awards include stock options for 375,000 shares and RSUs for 187,500 shares, aimed at incentivizing Ahuja's long-term commitment to the company. These grants comply with Nasdaq Listing Rule 5635(c)(4) and are structured to vest over four years.
Read more →MXCTMaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MaxCyte, Inc. has announced the granting of inducement awards to Parmeet Ahuja, its new Chief Financial Officer. The awards include stock options for 375,000 shares and RSUs for 187,500 shares, aimed at incentivizing his employment. These awards comply with Nasdaq Listing Rule 5635(c)(4) and are structured to vest over four years.
Read more →MXCT▼ -6.8%on this news
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
MaxCyte, Inc. reported its financial results for Q4 and full year 2025, revealing total revenues of $7.3 million for the fourth quarter and $33.0 million for the year. The company anticipates revenue of $30-32 million for 2026, despite facing challenges from a major customer. MaxCyte has made strides in reducing cash burn and expanding its SPL portfolio, positioning itself for potential growth in the cell therapy market.
Read more →MXCTMaxCyte Appoints Parmeet Ahuja as Chief Financial Officer
MaxCyte, Inc. has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Ahuja succeeds Douglas Swirsky and brings over 20 years of finance leadership experience from Agilent Technologies. CEO Maher Masoud expressed confidence in Ahuja's ability to enhance financial operations and support the company's growth strategy.
Read more →MXCT▲ +5%on this news
MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discovery
MaxCyte has launched ExPERT DTx™, a 96-well electroporation platform designed to improve research and drug discovery. This modular system allows for high throughput transfection with minimal cellular stress, streamlining workflows and enhancing experimental consistency. The platform features advanced software for remote experiment design, maximizing efficiency in laboratory settings.
Read more →MXCT▲ +5%on this newsshared move
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026
MaxCyte, Inc. will announce its fourth quarter and full year 2025 financial results on March 24, 2026. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results. Investors are encouraged to register online for the call, which will also be available via a live and archived webcast.
Read more →MXCTMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results ROCKVILLE, MD
MaxCyte, Inc. has announced its preliminary unaudited financial results for the fourth quarter and full year 2025, indicating an expected total of approximately $155.6 million in cash and investments. Despite facing a challenging year, the company reported core revenue in line with guidance and anticipates returning to revenue growth in the latter half of 2026. CEO Maher Masoud emphasized the company's efforts to streamline operations and enhance cost structures for efficient growth going forward.
Read more →MXCTMaxCyte Announces Planned CFO Transition in 2026
MaxCyte, Inc. has announced that CFO Douglas Swirsky will transition from his role in the first half of 2026. The company is initiating a search for his successor, and Swirsky will remain in his position until a replacement is appointed. He will continue to support the company in an advisory capacity post-transition. The leadership change is not expected to disrupt operations or strategic priorities.
Read more →MXCTMaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance
MaxCyte, Inc. reported its third quarter 2025 financial results, indicating a 16% decrease in total revenue compared to the previous year. The company reiterated its revenue guidance for 2025 and highlighted an operational restructuring aimed at cost reduction and long-term growth. Despite a challenging environment, MaxCyte remains committed to its strategic initiatives and partnerships.
Read more →MXCTMaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MaxCyte will now host its earnings conference call on
MaxCyte, Inc. has reported preliminary financial results for the third quarter of 2025, indicating a decline in core revenue by 21% compared to the previous year. Despite this decline, the company has reiterated its revenue guidance for the full year, expecting to finish with total cash between $152 million and $155 million. A substantial increase in program-related revenue was noted, growing by 1,663%, though the company is facing challenges with financial reporting, leading to a delay in its earnings release. Management is currently conducting an impairment test on certain assets as part of its financial review.
Read more →MXCT▲ +9.7%on this news
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
MaxCyte, Inc. announced it will release its financial results for the third quarter of 2025 on November 5, 2025, after market close. The company will host a conference call at 4:30 p.m. ET to discuss these results. Investors are encouraged to register online in advance to participate in the call.
Read more →MXCTMaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors
MaxCyte has entered a Strategic Platform License agreement with Moonlight Bio to enhance the development of T cell therapies targeting solid tumors. This partnership will leverage MaxCyte's Flow Electroporation technology and ExPERT platform, which are designed for scalable and efficient cell engineering. Moonlight Bio aims to address the challenges faced in treating solid tumors, which represent a significant portion of cancer cases globally.
Read more →MXCT▲ +10.3%on this news
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
MaxCyte, Inc. has announced a significant operational restructuring aimed at reducing costs and aligning resources with its strategic priorities. The plan includes a workforce reduction of about 34%, which is expected to save the company approximately $13.6 million annually. Despite these changes, MaxCyte maintains its focus on advancing cell therapies, although it anticipates a decline in core revenue for 2025.
Read more →MXCTMaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance ROCKVILLE, MD
MaxCyte, Inc. reported its second quarter financial results for 2025, showing a total revenue decline of 18% compared to the previous year. Despite an 8% increase in core business revenue, the company has downgraded its revenue guidance for the year due to challenges related to customer inventory and pipeline consolidation. MaxCyte remains focused on maintaining operational efficiency and enhancing its product offerings, expressing confidence in the long-term prospects within the cell and gene therapy sector.
Read more →MXCTMaxCyte Signs Platform License Agreement with Adicet Bio
MaxCyte has entered a strategic platform license agreement with Adicet Bio, granting the latter rights to use MaxCyte's Flow Electroporation technology and ExPERT platform. This collaboration aims to enhance Adicet's gamma delta T cell therapy programs, which target cancer and autoimmune diseases. MaxCyte will receive licensing fees and potential revenue from related programs.
Read more →MXCTMaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline
MaxCyte has entered into a Strategic Platform License Agreement with Anocca AB to utilize its Flow Electroporation technology and ExPERT platform for developing TCR-T cell therapies. This partnership aims to enhance Anocca's capabilities in scalable manufacturing and clinical development. Anocca has recently achieved GMP compliance for its production facility, further supporting its therapeutic pipeline.
Read more →MXCTMaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025
MaxCyte, Inc. has announced the release date for its second quarter 2025 financial results, set for August 6th, 2025. After market close, the company will provide insights through a conference call scheduled for 4:30 p.m. Eastern Time. Investors are required to register online to listen to the call, demonstrating MaxCyte's commitment to transparency and investor communication.
Read more →MXCTMaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech have announced a strategic partnership to enhance manufacturing efficiencies in cell and gene therapy. This collaboration will leverage MaxCyte's ExPERT platform and Ori's IRO platform to improve the efficiency and scalability of cell therapy production, specifically focusing on CD19 CAR expression using CRISPR technology. Both companies emphasize their commitment to accelerating the development of transformative therapies for patients through integrated, best-of-breed solutions. The initiative highlights the ongoing evolution in cell therapy manufacturing aimed at increasing access to next-generation treatments globally.
Read more →MXCTMaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance ROCKVILLE, MD
MaxCyte, Inc. announced its first quarter financial results for 2025, reporting a total revenue of $10.4 million, down 8% from the previous year. Despite this decline, the company achieved a modest core revenue growth of 1%, largely driven by sales to its SPL clients. Key highlights included the integration of SeQure Dx and the addition of a new SPL client. The company maintains its revenue guidance for 2025 and remains optimistic about enhancing its operational capabilities for long-term growth.
Read more →MXCT▼ -7.5%on this news
MaxCyte to Report First Quarter 2025 Financial Results on May 7, 2025
MaxCyte, Inc. announced it will release its financial results for the first quarter of 2025 after market close on May 7, 2025. The company is known for its focus on cell engineering technologies for therapeutics. Following the release, a conference call will be hosted by management to discuss the results and stakeholders are encouraged to register in advance to listen. A webcast of the event will be available on MaxCyte's investor website.
Read more →MXCTMaxCyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Full Year 2025 Guidance ROCKVILLE, MD
MaxCyte, Inc. reported its financial results for the fourth quarter and full year of 2024, revealing a 45% decrease in total revenue for Q4 compared to the previous year. However, core revenue saw a growth of 20%, driven by improved sales in instruments, PAs, and consumables. The company also initiated its 2025 guidance, expecting continued growth in core business revenue. Despite these positive metrics, MaxCyte faced a significant net loss and a sharp decline in SPL Program-related revenue during the same quarter.
Read more →MXCTMaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs
MaxCyte, Inc. has entered into a strategic platform license with TG Therapeutics, granting the latter rights to utilize MaxCyte's Flow Electroporation technology and ExPERT platform for cell-based therapies. This collaboration is particularly aimed at advancing TG Therapeutics' investigational CD19 CAR T cell therapy, azer-cel, for treating progressive forms of multiple sclerosis. The agreement also specifies that MaxCyte will receive annual licensing fees and program-related revenue as compensation for the use of its technology. The partnership reflects a significant step towards the commercialization of innovative treatments for autoimmune diseases using advanced cell-engineering methods.
Read more →MXCTMaxCyte to Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025, and Participate in Upcoming Investor Conference
MaxCyte, Inc. announced it will release its financial results for Q4 and the full year 2024 on March 11, 2025. The company will hold a conference call to discuss these results after the market closes. Additionally, MaxCyte will participate in the 45th Annual TD Cowen Healthcare Conference on March 3, where management will be available for a fireside chat. Investors are encouraged to register for the conference call and will have access to a webcast of the events.
Read more →MXCTMaxCyte Acquires SeQure Dx to Broaden Cell Engineering Offerings with On-target and Off-target Editing Assessments ROCKVILLE, MD
MaxCyte, Inc. has announced the acquisition of SeQure Dx, a leader in on-target and off-target editing assessments, to enhance its offerings in cell and gene therapy. This acquisition aims to improve the precision and safety of cell engineering solutions by integrating advanced assays provided by SeQure Dx. The deal involves an initial payment of $4.5 million, with potential contingent payments based on performance. Despite SeQure Dx's past financial losses, MaxCyte expects significant operational and revenue improvements through this strategic integration.
Read more →MXCT▲ +11.6%on this news
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results ROCKVILLE, MD
MaxCyte, Inc. announced preliminary unaudited financial results for the fourth quarter and full year of 2024, reporting core revenue at the high end of its guidance. The company indicated an improvement in the operating environment for the cell therapy industry and highlighted significant achievements, including the commercial launch of a non-viral gene therapy. However, total cash and investments declined from the previous year. Results remain preliminary and subject to change before the audited financial statements are released in March 2025.
Read more →MXCTMaxCyte Announces Retirement of Board Member Art Mandell ROCKVILLE, MD
MaxCyte, Inc. announced the retirement of Art Mandell from its Board of Directors effective December 31, 2024, after serving since 2006. Throughout his tenure, the company has seen substantial achievements, including significant partnership agreements and a successful initial public offering. Mandell expressed pride in his time at MaxCyte, highlighting its future potential in developing cutting-edge cell and gene therapies. With his departure, the Board will comprise nine members moving forward.
Read more →MXCT▲ +15.8%on this news
MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance ROCKVILLE, MD
MaxCyte, Inc. has announced the completion of an operational review aimed at streamlining its operations, resulting in workforce adjustments that affected 21 positions. This move is intended to improve efficiency and align resources with the company's strategic priorities. As a result, MaxCyte has raised its 2024 revenue guidance to project a 6% to 8% growth compared to the previous year. The company anticipates cost savings of approximately $5.8 million in 2025, further supporting its strategic initiatives in cell therapy manufacturing.
Read more →MXCTMaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
MaxCyte, a leader in cell-engineering technologies, celebrates its 25th anniversary, emphasizing its commitment to advancing cell therapeutics. The company has notably contributed to the development of the industry’s first FDA-approved non-viral cell therapy, CASGEVY, and has formed 29 Strategic Platform License agreements with various cell therapy developers. Their recent move to a larger facility in Maryland signifies an expansion in manufacturing and research capabilities. Looking ahead, MaxCyte aims to leverage its innovative technologies to support next-generation bio-medications.
Read more →MXCTMaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD
MaxCyte, Inc. reported its financial results for Q3 2024, revealing a total revenue of $8.2 million, a slight increase from the previous year. The company has signed a record number of six new SPL clients this year, while emphasizing a strong outlook for the remainder of 2024. Despite the revenue growth in core business areas, the company experienced increased net losses and significant declines in specific revenue segments. MaxCyte has also updated its revenue guidance, projecting at least 5% growth for core business revenue in 2024.
Read more →MXCTMaxCyte to Participate in Two Upcoming Investor Conferences
MaxCyte, Inc. announced its participation in two upcoming investor conferences scheduled for November 2024. The conferences include the Stifel 2024 Healthcare Conference and the Stephens Annual Investment Conference. MaxCyte's management will engage in fireside chats at both events, which will also be available via webcast on the company's investor relations website. This participation highlights the company's focus on investor engagement and corporate visibility.
Read more →MXCTMaxCyte Appoints Cynthia Collins to its Board of Directors Rockville, MD
MaxCyte, Inc. announced the appointment of Cynthia Collins to its Board of Directors, effective October 14, 2024. Collins, who has over 40 years of experience in biotechnology and cell therapy, will also serve on the board's compensation committee. Her previous roles include CEO of Editas Medicine and Human Longevity Inc. Following her appointment, the Board will have a total of 10 members. MaxCyte aims to leverage her expertise to drive advancements in cell-based therapeutics.
Read more →MXCTMaxCyte to Report Third Quarter 2024 Financial Results on November 6, 2024
MaxCyte, Inc. has announced that it will release its financial results for the third quarter of 2024 on November 6, 2024, after U.S. market close. Following this release, management will hold a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors will need to register in advance if they wish to participate, with a live webcast also being made available on MaxCyte's website.
Read more →MXCTMaxCyte Appoints Ali Soleymannezhad as Chief Commercial Officer
MaxCyte, Inc. announced the appointment of Ali Soleymannezhad as Chief Commercial Officer effective September 11, 2024. In this role, he will oversee commercial operations and aim to expand market impact in cell and gene therapy. Soleymannezhad brings two decades of experience in technical sales, marketing, and product development, previously serving as Executive Vice President of Bioprocessing at MaxCyte. The leadership change is intended to enhance the company's growth trajectory and customer support abilities in the growing biopharmaceutical market.
Read more →MXCTMaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
MaxCyte has signed a strategic platform license agreement with Kamau Therapeutics to facilitate the development of innovative cell therapies targeting genetic diseases, specifically sickle cell disease (SCD). Under this agreement, Kamau gains access to MaxCyte's Flow Electroporation technology, enabling enhanced gene editing and optimizing clinical manufacturing processes. This partnership marks MaxCyte's 29th collaboration aimed at improving patient outcomes and addressing unmet medical needs in genetic therapy. Kamau's lead program, nula-cel, aims to precisely correct genetic mutations associated with SCD, potentially revolutionizing treatment options for affected patients.
Read more →MXCTMaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference
MaxCyte, Inc. has announced its participation in the upcoming Virtual Craig-Hallum Capital Group Bioprocessing Conference scheduled for September 19th at 9:30 am ET. This event highlights the company's commitment to advancing cell-engineering and bioprocessing applications. A replay of the conference will be available on MaxCyte's investor relations website.
Read more →MXCTMaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance ROCKVILLE, MD
MaxCyte, Inc. reported its financial results for the second quarter and first half of 2024, highlighting a 15% increase in total revenue year-over-year. The company affirmed its revenue guidance, projecting core business revenue to remain flat to a 5% growth. Despite facing a decline in core business revenue and increased operating expenses, positive growth in SPL Program-related revenue was noted. Management expressed confidence in the company's position and role in cell therapy development.
Read more →MXCTMaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
MaxCyte, Inc. has announced that it will release its financial results for the second quarter of 2024 on August 6th, 2024, after the U.S. market closes. Following the release, company management will host a conference call at 4:30 p.m. Eastern Time to discuss these results. Interested investors can listen to the call by registering online in advance.
Read more →MXCTMaxCyte to Participate in William Blair 44th Annual Growth Stock Conference
MaxCyte, Inc. will participate in the William Blair 44th Annual Growth Stock Conference on June 5th at 2:40 pm CT. This event signifies the company's commitment to engaging with investors and increasing its visibility in the biopharma space. Attendees can access a live and archived webcast of the event on the company's investor relations website.
Read more →MXCTMaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development
MaxCyte, Inc. has entered into a strategic platform license agreement with Legend Biotech, allowing Legend to utilize MaxCyte's Flow Electroporation technology in the development of cell-based therapeutics. This partnership not only enables Legend to expand its therapeutic portfolio but also provides MaxCyte with potential annual licensing fees and royalties from successful product commercialization. The collaboration aims to enhance manufacturing processes and accelerate the growth of non-viral engineered cell therapy programs.
Read more →MXCTMaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance ROCKVILLE, MD
MaxCyte, Inc. announced its financial results for the first quarter of 2024, showing a 32% increase in total revenue compared to the same period in 2023. The company achieved core revenue growth of 5%, driven by strong commercial execution and demand from cell therapy clients. MaxCyte also updated its revenue guidance for the year, increasing expectations for SPL Program-related revenue while affirming overall core revenue growth projections. Despite these positive strides, the company reported a net loss of $9.5 million, although this was an improvement from the prior year's losses.
Read more →MXCTMaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024
MaxCyte, Inc. announced its plan to release the financial results for the first quarter of 2024 on May 7, 2024, after the U.S. market closes. Following the release, the company will host a conference call at 4:30 PM Eastern Time to discuss the results. Investors are encouraged to register online for the call. An archived webcast of the event will also be available on the MaxCyte website.
Read more →MXCTMaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)
MaxCyte, Inc. has signed a strategic platform license with Be Biopharma to facilitate the development of Engineered B Cell Medicines (BCMs). This agreement grants Be Bio non-exclusive rights to utilize MaxCyte's advanced Flow Electroporation technology and ExPERT platform. In return, MaxCyte will receive licensing fees and revenue from successful programs. MaxCyte's support aims to empower Be Bio in addressing unmet medical needs for patients with various serious health conditions.
Read more →MXCTMaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance ROCKVILLE, MD
MaxCyte, Inc. reported its financial results for the fourth quarter and full year 2023, showing a total revenue growth of 26% compared to Q4 2022. Despite the positive growth in SPL program-related revenue and optimistic guidance for 2024, the core business faced substantial declines, particularly in cell therapy and drug discovery revenues. The company also recorded an increase in net loss and operating expenses, raising concerns over profitability. Management remains confident in navigating the challenges and anticipates further growth in its SPL client pipeline.
Read more →MXCTMaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results ROCKVILLE, MD
MaxCyte, Inc. has announced its revenue guidance for the full year 2024 and reaffirmed its preliminary results for 2023. The company projects total revenues for 2023 to be between $41.1 million and $41.3 million, a decline compared to $44.3 million in 2022. Despite this, management is optimistic about future growth, citing new SPL agreements and a solid cash position. Additionally, the company will present at the Cowen Healthcare Conference and release its final financial results for 2023 in mid-March.
Read more →MXCTMaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
MaxCyte, Inc. will report its fourth quarter and full year 2023 financial results on March 12, 2024, after market close. Following the release, the company will hold a conference call at 4:30 PM ET to discuss the results with investors. Additionally, it will participate in upcoming investor conferences, including the BTIG MedTech Conference and the Cowen Healthcare Conference, demonstrating its commitment to investor relations and market engagement.
Read more →MXCTMaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
MaxCyte, Inc. and Wugen, Inc. have announced a strategic platform license agreement aimed at advancing Wugen's allogeneic, off-the-shelf cell therapies for cancers. Through this agreement, Wugen will utilize MaxCyte's Flow Electroporation technology and ExPERT platform for enhanced manufacturing capabilities. Wugen's lead therapy, WU-CART-007, is under evaluation for relapsed or refractory T-cell acute lymphoblastic leukemia, having received FDA orphan and fast-track designations. This partnership marks a significant step in developing innovative cancer treatments.
Read more →MXCTMaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
MaxCyte has signed a strategic platform license with Imugene, granting the latter non-exclusive rights to use MaxCyte's Flow Electroporation technology and ExPERT platform for their cancer immunotherapy programs. This collaboration will facilitate the development of Imugene's azer-cel, an allogeneic CAR T cell therapy currently in clinical trials for non-Hodgkin’s lymphoma. The partnership exemplifies a significant step toward advancing cancer treatment options and improving patient outcomes.
Read more →MXCTMaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results ROCKVILLE, MD
MaxCyte, Inc. has announced its preliminary unaudited financial results for the fourth quarter and full year 2023. Expected total revenue for Q4 is forecasted between $15.5 million and $15.7 million, an increase from $12.4 million in Q4 2022. However, total revenue for the fiscal year is predicted to decline to between $41.1 and $41.3 million compared to $44.3 million in 2022. The company also reported having approximately $210 million in cash and investments, while highlighting its role in the FDA approval of CASGEVY, a significant milestone in cell therapy.
Read more →MXCT▼ -11.6%on this newsshared move
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
MaxCyte and Lion TCR have entered into a strategic partnership to support the global expansion of Lion TCR's TCR-T cell therapy pipeline, particularly for hepatocellular carcinoma and viral infections. Under the agreement, Lion TCR gains worldwide rights to utilize MaxCyte's Flow Electroporation and ExPERT platforms. This collaboration will enhance patient access to innovative therapies and is aimed at bolstering both companies' presence in key global markets. Lion TCR has also received FDA approval for a pioneering trial of its HBV TCR-T therapy.
Read more →MXCT▲ +6.4%on this newsshared move
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
MaxCyte, Inc. has officially announced the appointment of Maher Masoud as President and Chief Executive Officer, effective January 1, 2024. Along with his new role, Mr. Masoud will serve as a director on the company's Board. Mr. Masoud has no prior directorship or partnership roles in the last five years, suggesting a clean slate for leadership at MaxCyte.
Read more →MXCTMaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023 Doug Doerfler, President and CEO, to Retire Effective
MaxCyte has announced the retirement of CEO Doug Doerfler, effective December 31, 2023, and named Maher Masoud as his successor starting January 1, 2024. The company is reaffirming its revenue guidance for 2023, with expectations of core business revenue between $28-30 million and SPL-related revenue surpassing $10 million. Under Doerfler's leadership, MaxCyte grew significantly and developed key technologies; Masoud plans to build upon these achievements. The announcement highlights both the transition in leadership and positive revenue outlook amid potential risks associated with upcoming clinical developments.
Read more →MXCTMaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
MaxCyte, Inc. has announced its membership in the Alliance for mRNA Medicines (AMM) as a founding member. The AMM aims to advance mRNA therapeutics and vaccines, promoting public health and scientific knowledge. MaxCyte's CEO emphasized the company's commitment to leveraging its electroporation technology to support the development of innovative mRNA applications. The AMM was launched at the 11th International mRNA Health Conference in Berlin, showcasing a collaboration among leading industry stakeholders.
Read more →MXCTMaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance ROCKVILLE, MD
MaxCyte, Inc. reports a decline in revenue for the third quarter of 2023, totaling $8.0 million, down 25% from the previous year. The company continues to face challenges as early-stage customers adjust their spending habits amid a cautious operating environment. Despite these challenges, MaxCyte remains optimistic about the long-term potential of the cell and gene therapy market and is making targeted strategic investments. The CEO reiterated confidence in expanding partnership portfolios and market opportunities related to cell therapies.
Read more →MXCT▲ +9%on this news
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance ROCKVILLE, MD
MaxCyte has reported preliminary revenue for the third quarter of 2023 and updated its full-year revenue guidance, citing a more challenging operating environment than previously expected. The company noted that customer activity in the life science tools sector is under pressure, with declines in processing assembly purchases and hesitancy around cell therapy instrument acquisitions. Despite these challenges, MaxCyte is optimistic about its long-term business model and ability to add shareholder value, highlighting a robust pipeline of partnerships and a projected cash position of $200 million at year-end. The final results for Q3 are expected to be released on November 8, 2023.
Read more →MXCTMaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
MaxCyte, Inc. appointed Ali Soleymannezhad as Executive Vice President of Bioprocessing, effective August 21, 2023. He will oversee product development and marketing strategy for the company's bioprocessing sector, utilizing the STx and VLx platforms. Soleymannezhad brings nearly 20 years of experience in biomanufacturing and aims to improve customer engagement and create innovative products to strengthen MaxCyte's market position.
Read more →MXCTMaxCyte to Participate in Baird Global Healthcare Conference
MaxCyte, a prominent cell-engineering company, announced its participation in the Baird Global Healthcare Conference scheduled for September 13th at 2:35 p.m. Eastern Time. The event aims to showcase advancements in cell-based research and therapeutic discovery. Investors can access a live and archived webcast of the event through the company's investor relations website.
Read more →MXCTMaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD
MaxCyte, Inc. reported its financial results for Q2 and the first half of 2023, showing a decline in total revenue compared to the previous year. Despite a challenging market environment and increased operational costs, the company signed five new strategic partnerships, bringing its total to 23. MaxCyte anticipates core revenue for 2023 to be on par with 2022, projecting unchanged expectations for program-related revenue. The CEO expressed commitment to advancing cell-based technologies and supporting partners through clinical development.
Read more →MXCTMaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
MaxCyte, Inc. has signed a strategic partnership with Prime Medicine to advance gene editing therapies. Under the agreement, Prime Medicine gains access to MaxCyte's Flow Electroporation technology and ExPERT platform. This partnership is expected to enhance the development of differentiated, one-time curative genetic therapies. MaxCyte will benefit from annual license fees and related revenues, marking its 23rd strategic partnership in this domain.
Read more →MXCTMaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
MaxCyte, Inc. has announced that it will release its financial results for the second quarter of 2023 on August 9, 2023, after U.S. market close. The company, which specializes in cell-engineering technologies, will host a conference call at 4:30 p.m. Eastern Time to discuss the financial outcomes. Interested investors are encouraged to register for the call in advance, with a live and archived webcast available on MaxCyte's website.
Read more →MXCT▲ +7.8%on this newsshared move
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
MaxCyte has entered into a strategic platform license agreement with Vittoria Biotherapeutics to utilize its Flow Electroporation® technology and ExPERT™ platform. This partnership aims to advance the development of innovative cellular therapies, particularly in oncology and immunology. Vittoria plans to file an investigational new drug application for its lead cellular therapy program, Viper 101, which is designed to treat T-cell lymphoma. MaxCyte's technologies are expected to enhance the safety and efficacy of these therapies.
Read more →MXCTMaxCyte Signs Strategic Platform License with Lyell Immunopharma
MaxCyte, Inc. has entered a strategic platform license agreement with Lyell Immunopharma, allowing Lyell to utilize MaxCyte's advanced Flow Electroporation technology and ExPERT platform for developing T cell therapies targeting solid tumors. This partnership provides Lyell with both clinical and commercial rights to the technology while benefiting MaxCyte through licensing fees and milestone payments. The collaboration underscores MaxCyte's commitment to advancing cell-based therapeutics and improving patient outcomes in serious medical conditions.
Read more →MXCTMaxCyte to Participate in Upcoming Investor Conferences
MaxCyte, Inc. announces its participation in two upcoming investor conferences: the William Blair 43rd Annual Growth Stock Conference on June 8 and the TD Cowen 2nd Annual Tools/Dx Revolution on June 26. The company's management will engage with investors to discuss advancements in cell-engineering technologies. A webcast of the William Blair presentation will be made available on MaxCyte's investor relations website. This participation reflects MaxCyte's commitment to advancing cell-based research and therapeutic development.
Read more →MXCTMaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD
MaxCyte, Inc. reported financial results for the first quarter of 2023, indicating a decrease in total revenue by 26% compared to Q1 2022. The company updated its annual revenue guidance, projecting growth between 8% and 12%. Despite the decline in Q1 revenue, MaxCyte secured two new Strategic Platform License partnerships, expanding its total partnerships to 20. The company reported a net loss of $10.9 million for the quarter, an increase from the previous year's loss.
Read more →MXCTMaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform
MaxCyte, Inc. has announced a strategic partnership with Walking Fish Therapeutics to support the development of B cell-based therapeutics. The agreement allows Walking Fish to use MaxCyte's Flow Electroporation technology and ExPERT platform, granting them non-exclusive clinical and commercial rights. In exchange, MaxCyte will receive platform licensing fees, clinical milestone payments, and sales-based payments. This collaboration marks MaxCyte's 20th strategic partnership, emphasizing its commitment to enabling advanced cell-based research and therapeutics.
Read more →MXCTMaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
MaxCyte, Inc. has announced its plans to report the financial results for the first quarter of 2023 on May 10, 2023. The results will be released after the U.S. market closes, followed by a conference call with company management to discuss the outcomes at 4:30 p.m. Eastern Time. Investors are encouraged to register for the call in advance and can access a live and archived webcast on the company's website.
Read more →MXCTMaxCyte Appoints Douglas Swirsky as Chief Financial Officer Rockville, MD
MaxCyte, Inc. has appointed Douglas J. Swirsky as its Chief Financial Officer, effective immediately. With over two decades of experience in the healthcare sector, Swirsky has previously held executive roles at various public companies, including AavantiBio, Inc. and Rexahn Pharmaceuticals, Inc. His appointment is expected to contribute significantly to MaxCyte's growth, as he aims to leverage his financial expertise to support the company's strategic goals. Ron Holtz, the former CFO, will transition to the role of Executive Vice President of Administration.
Read more →MXCTMaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results 31% Total Revenue Growth for Full Year 2022 including 26% Core Business Revenue Growth and $4.6 million in Program-related Revenue ROCKVILLE, MD
MaxCyte, Inc. reported its financial results for the fourth quarter and full year of 2022, achieving a total revenue growth of 31%. Core business revenue also showed strong performance, growing by 26%, attributed to heightened demand for its cell therapy and drug discovery products. The company has made considerable investments in infrastructure, which positions it well for continued growth. However, it noted a net loss of $23.6 million for the year, indicating ongoing financial challenges despite the positive revenue trends.
Read more →MXCTMaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
MaxCyte, Inc. has established a new Scientific Advisory Board consisting of prominent experts in cell engineering and molecular design. This initiative aims to enhance the company's leadership and scientific expertise in developing cell-based therapies. The board includes distinguished professionals from top institutions who will provide guidance and innovation to support MaxCyte's ongoing projects and improve therapeutic applications. This development represents a strategic move towards advancing the company's research and development capabilities in the biopharmaceutical sector.
Read more →MXCT▼ -7.5%on this newsshared move
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance Full year 2022 total revenue expected to be approximately $44.3 million, representing growth of
MaxCyte, Inc. announced preliminary revenue results for the fourth quarter and full year 2022, with total revenue expected to reach approximately $44.3 million, reflecting a 31% increase from 2021. The company has also provided initial 2023 revenue guidance, forecasting growth between 21% and 26%. Significant advancements include the addition of new strategic partnerships, contributing to their growing collaboration portfolio. MaxCyte continues to strongly support the field of cell therapy through its innovative technologies and expanding market presence.
Read more →MXCTMaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
MaxCyte, Inc. has announced that it will release its financial results for the fourth quarter and full year 2022 on March 15, 2023, after market close. The company will host a conference call at 4:30 p.m. ET to discuss these results. Furthermore, MaxCyte is set to participate in key investor conferences, such as the BIO CEO & Investor Conference and the Cowen Healthcare Conference, highlighting its engagement with investors and stakeholders in the biotech sector.
Read more →MXCT▼ -6.2%on this news
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
MaxCyte, Inc. has entered into a strategic platform license agreement with Catamaran Bio to advance CAR-NK cell therapy programs targeting solid tumors. Under the agreement, Catamaran Bio gains rights to utilize MaxCyte's Flow Electroporation technology and ExPERT platform for its cancer treatment initiatives. This partnership is expected to leverage synthetic biology to improve the efficacy of off-the-shelf CAR-NK therapies. The agreement marks MaxCyte's 19th strategic platform license overall, highlighting the company's ongoing commitment to support innovative cell-based research and therapy development.
Read more →MXCT▼ -10.7%on this news
MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases
ROCKVILLE, Md. and SEOUL, South Korea, Dec. 04, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation c
Read more →MXCTMaxCyte Appoints Patrick J. Balthrop as Non-Executive Director Rockville, MD, 1 December, 2022: MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell - engineering focused company providing enabling platform technolo
MaxCyte Appoints Patrick J. Balthrop as Non-Executive 1 December, 2022: MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation
Read more →MXCT▼ -9.4%on this news
MaxCyte Reports Third Quarter 2022 Financial Results 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, MD
MaxCyte Reports Third Quarter 2022 Financial Results 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, MD, November 9, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company p
Read more →MXCTMaxCyte to Report Third Quarter 2022 Financial Results on November 9, 2022
ROCKVILLE, Md., Oct. 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic disc
Read more →MXCT▲ +7.6%on this news· ran to +20% by day 3
MaxCyte Signs Strategic Platform License with Vertex Pharmaceuticals to Advance CRISPR/Cas9-based Gene-editing Program
Vertex Pharmaceuticals will continue to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support gene-edited cell therapy exa-cel, formerly known as CTX001™ for hemoglobinopathies ROCKVILLE, Md., Sept. 28, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MX
Read more →MXCTMaxCyte Debuts New State-of-the-Art Headquarters in Maryland’s I-270 Biotech Corridor
Expanded facilities illustrate MaxCyte’s commitment to Montgomery County and the state of Maryland, building the life sciences community, and propelling local job opportunities. ROCKVILLE, Md., Sept. 21, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leadin
Read more →MXCTMaxCyte to Participate in Morgan Stanley 20th Annual Global Healthcare Conference
ROCKVILLE, Md., Sept. 07, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic dis
Read more →MXCTMaxCyte Reports Second Quarter and Half-Year 2022 Financial Results 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, MD
MaxCyte Reports Second Quarter and Half-Year 2022 Financial Results 45% Year-Over-Year Core Business Revenue Growth in Second Quarter 2022 Raises 2022 Core Revenue Growth Guidance to Approximately 30% ROCKVILLE, MD, August 10, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a
Read more →MXCTMaxCyte to Report Second Quarter 2022 Financial Results on August 10, 2022
GAITHERSBURG, Md., July 15, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic d
Read more →MXCTMaxCyte Signs Strategic Platform License with LG Chem to Advance its Allogeneic CAR-T Programs
GAITHERSBURG, Md., July 12, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic d
Read more →MXCTMaxCyte Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic di
Read more →MXCTMaxCyte Reports First Quarter Financial Results MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million GAITHERSBURG, MD
MaxCyte Reports First Quarter Financial Results MaxCyte Increases 2022 Core Revenue Growth Guidance to be at least 25% and Reiterates Milestone Revenue Guidance of $4 million GAITHERSBURG, MD, May 9, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-eng
Read more →MXCTMaxCyte Reports First Quarter Financial Results
GAITHERSBURG, Md., May 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic di
Read more →MXCTMaxCyte to Report First Quarter 2022 Financial Results on May 9, 2022
GAITHERSBURG, Md., April 20, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic
Read more →MXCTMaxCyte Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD
Announces Departure of CFO and Appointment of Ron Holtz as Interim CFO, Announces Preliminary First Quarter 2022 Revenue GAITHERSBURG, MD, April 12, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling plat
Read more →MXCTMaxCyte Reports Fourth Quarter and Full Year Financial Results MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, MD
MaxCyte Reports Fourth Quarter and Full Year Financial Results MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, MD, March 22, 2022 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies
Read more →MXCTMaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer
GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therap
Read more →MXCTMaxCyte to Report Fourth Quarter and Full Year 2021 Financial Results on March 22, 2022
GAITHERSBURG, M.D., Feb. 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therap
Read more →MXCTMaxCyte Signs Strategic Platform License with Intima Bioscience to Advance Tumor Infiltrating Lymphocytes Programs
NEW YORK and GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with Intima Biosc
Read more →MXCT▲ +5.3%on this news
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results Fourth quarter 2021 revenue expected to be greater than $10 million Full year 2021 revenue expected to be greater than $33.
MaxCyte Announces Strong Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenue Results GAITHERSBURG, MD., January 24, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling
Read more →MXCT▼ -7.7%on this newsshared move
MaxCyte Reports Third Quarter Financial Results GAITHERSBURG, MD
MaxCyte Reports Third Quarter Financial Results MD, November 10, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-g
Read more →MXCT▼ -7.7%on this newsshared move
MaxCyte Reports Third Quarter Financial Results
GAITHERSBURG, Md., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therape
Read more →MXCTMaxCyte Board Member Richard Douglas, PhD, Appointed Chairman of the Board
GAITHERSBURG, Md., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell thera
Read more →MXCTMaxCyte Signs Strategic Platform License with Nkarta, Inc. to Advance Natural Killer Cell Therapy Programs
SOUTH SAN FRANCISCO and GAITHERSBURG, Md., Oct. 28, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex-vivo cell engineering, today announces the signing of a strategic platform license (SPL) with N
Read more →MXCTMaxCyte to Report Third Quarter 2021 Financial Results on November 10, 2021
GAITHERSBURG, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therape
Read more →MXCTMaxCyte Set to Join Russell 2000 Index
GAITHERSBURG, Md., Sept. 17, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therap
Read more →MXCTMaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections GAITHERSBURG, MD
MaxCyte Reports Second Quarter and Half-Year 2021 Financial Results Provides Preliminary 2021 Revenue Projections GAITHERSBURG, MD, September 13, 2021 - MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading commercial cell engineering company focused on providing enablin
Read more →MXCT▲ +7.5%on this news
MaxCyte to Report Second Quarter 2021 Financial Results on September 13, 2021
GAITHERSBURG, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT, MXCN), a leading provider of enabling platform technologies for ex vivo cell engineering, today announced that it will release financial results for the second quarter of 2021 after the
Read more →Competitive Position
How MXCT ranks across every disease it competes inCompetitive Position is a premium feature
See how MXCT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial